Associate Director, Hematology

Role Summary
The Associate Director, Hematology supports the development and execution of global commercial strategies and tactics for assigned pipeline and early lifecycle assets within the Hematology Therapeutic Area (TA). Reporting to the Director, Hematology, this role combines strategic, project‑based commercial work (~70%) with structured project management responsibilities (~30%) to ensure timely, high‑quality delivery of critical commercialization milestones.

The primary asset responsibility will be VMX‑C001, with additional projects assigned across the Hematology portfolio as bandwidth permits. This role partners closely with R&D, US and International Commercial teams, Market Access, Medical Affairs, Insights and analytics and other cross‑functional stakeholders to ensure alignment and executional excellence.

Key Responsibilities

Strategic & Project‑Based Commercial Contributions (≈70%)

• Support the development and execution of global commercial strategies and tactics for   Hematology assets, aligned with TA strategy and lifecycle plans.

• Contribute to strategic commercial planning, including brand vision elements, strategic imperatives, and early value narratives

• Support development of go‑to‑market components (e.g., launch plan, positioning, value proposition inputs) in collaboration with US and International Commercial stakeholders.

• Contribute to key commercial deliverables for the Hematology portfolio during the T‑36 to launch period (e.g.: include segmentation, unbranded and branded campaigns, messaging development, media plan etc.) to ensure continuity, preparedness, and alignment across cross functional partners

• Lead planning for workshops at congresses engaging appropriate internal and external team members incl.  CSL 3M teams from Int, regional affiliates and US

• Serve as a contributing member for market research projects synthesizing customer, payer, and competitive insights to inform opportunity assessment and strategic decision‑making.

• Support content development for leadership reporting 

• Lead other ah-hoc projects as assigned

Project Management & Execution (≈30%)

• Lead defined projects or workstreams within the Hematology portfolio, operating within established objectives, timelines, and governance structures.

• Develop and maintain IGNITE project plans, milestones, dependencies, and risk mitigation strategies to support on‑time delivery.

• Coordinate cross‑functional stakeholders to ensure clarity of roles, alignment on deliverables, and disciplined execution.

• Provide structured updates, issue escalation, and recommendations

• Support governance forums through preparation of materials, documentation of decisions, and follow‑up on action items.

Qualifications

• Bachelor’s degree in business, marketing, life sciences, or healthcare discipline required; MBA or advanced degree preferred.

• 10+ years of experience in pharmaceutical or biotechnology roles across commercial, strategy, marketing, or cross‑functional project management.

• Experience supporting pipeline assets and/or early commercialization activities.

• Demonstrated ability to manage complex projects with multiple stakeholders.

• Hematology and/or rare disease experience preferred.

Leadership & Behavioral Capabilities (CSL‑aligned)

• Operates effectively within defined strategic direction while exercising sound judgment and executional discipline.

• Builds productive cross‑functional partnerships and contributes positively to team outcomes.

• Demonstrates learning agility and comfort working in evolving and ambiguous environments.

• Communicates clearly and concisely with stakeholders at multiple organizational levels.

• Takes accountability for assigned deliverables and proactively identifies risks and opportunities.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.

CSL Behring operates one of the world’s largest